Skip to main content
SpringerLink
Log in

Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Flecainide is used as a pill-in-the-pocket treatment for pharmacological cardioversion in patients without structural heart disease and atrial fibrillation (AF). In patients with structural heart disease and elevated cardiovascular risk, flecainide is believed to be harmful. Therefore, data about safety and effectiveness of single-dose flecainide for cardioversion in patients at elevated cardiovascular risk are lacking.

Objectives

One-hundred and six consecutive patients with recent onset AF and known structural heart disease and/or elevated PROCAM-score did receive oral flecainide 300 mg for cardioversion.

Methods

The effectiveness, safety and influencing factors of flecainide for cardioversion in high-risk patients were prospectively assessed.

Results

In 43 of 106 patients (40.6%), sinus rhythm could be restored within 192.4 ± 10.7 min by flecainide. The PROCAM-score was 41.5 ± 0.56 in patients with successful cardioversion compared to 45.7 ± 0.74 in patients without successful cardioversion (P < 0.001). ACE-inhibitor co-medication was associated with a significantly lower rate of conversion by flecainide (HR 2.3, 95% CI, 1.12–4.26, P < 0.01). In 58 of 63 patients in whom cardioversion by flecainide was not effective, electrical cardioversion was performed which was successful in 47 patients. Life-threatening arrhythmias did not occur in any patient. The most common side effect was sinus-bradycardia and transient sinus arrest (2–4 s) immediately after conversion.

Conclusions

When monitored properly, flecainide is safe and useful for cardioversion in patients at elevated cardiovascular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833

    CAS  PubMed  Google Scholar 

  2. Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY (1995) Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 75(10):693–697

    Article  CAS  PubMed  Google Scholar 

  3. Donovan KD, Dobb GJ, Coombs LJ, Lee KY, Weekes JN, Murdock CJ, Clarke GM (1992) Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 70(5):50A–54A (discussion 54A-55A)

    Article  CAS  PubMed  Google Scholar 

  4. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos JM, Camacho C (2000) Comparison of intravenous flecainide, propafenone. and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 86(9):950–953

    Article  CAS  PubMed  Google Scholar 

  5. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggioli G (2004) Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 351(23):2384–2391

    Article  CAS  PubMed  Google Scholar 

  6. Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA (1991) Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investig Am J Cardiol 68(17):1551–1555

    CAS  Google Scholar 

  7. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12):781–788

    Article  CAS  PubMed  Google Scholar 

  8. Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327(4):227–233

    Article  Google Scholar 

  9. Teo KK, Yusuf S, Furberg CD (1993) Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270(13):1589–1595

    Article  CAS  PubMed  Google Scholar 

  10. Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105(3):310–315

    Article  PubMed  Google Scholar 

  11. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Bocker D, Breithardt G, Haverkamp W, Borggrefe M (2002) Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360(9342):1275–1279

    Article  PubMed  Google Scholar 

  12. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23):1834–1840

    Article  PubMed  Google Scholar 

  13. Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation–Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244):1789–1794

    Article  CAS  PubMed  Google Scholar 

  14. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41(10):1690–1696

    Article  PubMed  Google Scholar 

  15. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126(2):476–486

    Article  PubMed  Google Scholar 

  16. Becker T, Kleemann T, Strauss M, Doenges K, Schneider S, Senges J, Seidl K (2008) Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised. Clin Res Cardiol 97(2):74–82

    Article  PubMed  Google Scholar 

  17. Kleemann T, Becker T, Donges K, Vater M, Gut B, Schneider S, Senges J, Seidl K (2007) The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease. Clin Res Cardiol 96(2):103–108

    Article  CAS  PubMed  Google Scholar 

  18. Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, Della Casa S, Binetti N, Cavazza M et al (1994) Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74(5):503–505

    Article  CAS  PubMed  Google Scholar 

  19. Crijns HJ, van Gelder IC, Lie KI (1988) Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 62(17):1303–1306

    Article  CAS  PubMed  Google Scholar 

  20. Alp NJ, Bell JA, Shahi M (2000) Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart 84(1):37–40

    Article  CAS  PubMed  Google Scholar 

  21. Iravanian S, Dudley SC Jr (2008) The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5(6 Suppl):S12–S17

    Article  PubMed  Google Scholar 

  22. Makkar KM, Sanoski CA, Spinler SA (2009) Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 29(1):31–48

    Article  CAS  PubMed  Google Scholar 

  23. Ehrlich JR, Hohnloser SH, Nattel S (2006) Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27(5):512–518

    Article  CAS  PubMed  Google Scholar 

  24. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S (2009) Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53(1):24–29

    Article  CAS  PubMed  Google Scholar 

  25. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA (2004) Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 1(6):669–675

    Article  PubMed  Google Scholar 

  26. Climent VE, Marin F, Mainar L, Gomez-Aldaravi R, Martinez JG, Chorro FJ, Roman P, Sogorb F (2004) Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 27(3):368–372

    Article  PubMed  Google Scholar 

  27. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360(7):668–678

    Article  CAS  PubMed  Google Scholar 

  28. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ (2008) Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117(12):1518–1525

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, Heart Center of the University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany

    Fikret Er, Orhan Aslan, Evren Caglayan, Natig Gassanov, Amir M. Nia, Erland Erdmann & Stephan Rosenkranz

Authors
  1. Fikret Er
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orhan Aslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evren Caglayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natig Gassanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amir M. Nia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erland Erdmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stephan Rosenkranz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fikret Er.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Er, F., Aslan, O., Caglayan, E. et al. Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. Clin Res Cardiol 99, 369–373 (2010). https://doi.org/10.1007/s00392-010-0129-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-010-0129-7

Keywords

Search

Navigation